NEW YORK (GenomeWeb News) - ExonHit Therapeutics has extended its license for Ariadne’s Pathway Studio software for its research projects in alternative RNA splicing, Ariadne said today.
Under the agreement, ExonHit will continue to use Pathway Studio in collaborations with drug development partners.
The software extracts functional relationships of genes, proteins, small molecules, cell processes, and diseases from the scientific literature and presents it in a database that can be used for analysis and for validating hypotheses.
ExonHit’s vice president of business development, John Jaskowiak, said the company has integrated the software into its target discovery processes “in order to identify pathways of interest and to prioritize splicing events that we will explore further in our research programs.”
Financial terms of the agreement were not released.